Non-viral nanovectors for gene delivery: factors that govern successful therapeutics

被引:44
|
作者
Viola, Joana R. [1 ]
El-Andaloussi, Samir [1 ]
Oprea, Iulian I. [1 ]
Smith, C. I. Edvard [1 ]
机构
[1] Karolinska Inst, Karolinska Univ Hosp Huddinge, Clin Res Ctr, Dept Lab Med, S-14157 Huddinge, Sweden
基金
瑞典研究理事会;
关键词
in vivo; intravenous administration; nanoparticles; receptor-mediated uptake; PLURONIC BLOCK-COPOLYMERS; CELL-PENETRATING PEPTIDES; LIPID-LIKE MATERIALS; IN-VIVO; TRANSGENE EXPRESSION; TARGETED DELIVERY; SKELETAL-MUSCLE; SIRNA DELIVERY; PLASMID DNA; NANOPARTICLES;
D O I
10.1517/17425241003716810
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Importance of the field: Gene therapy is regarded as one of the most promising therapeutic approaches, as it has the potential to treat disorders by correcting malformations at the nucleic acids. Areas covered in this review: Some of the most recent developments in the process of plasmid DNA vector design and formulation are reviewed with a special focus on: different formulations of nanovectors and a summary of successful cases reported; requirements for systemic administration; and functionalization of the nanocarriers by use of targeting entities. What the reader will gain: An understanding of the different physiological barriers and a comprehensive review of the recent strategies used to overcome these obstacles. Particular attention is given to formulations for intravenous administration, colloidal stability properties and different targeting entities used. Take home message: Overall, vector formulation must take into account the administration route and inherent physiological barriers. Critical parameters for the success of pDNA nanovectors are: particles size, colloidal stability of the formulation and interaction between the carrier and plasmid DNA. Highly relevant is the fact that this interaction should be balanced to offer protection to degradation as well as allow dissociation of the therapeutic nucleic acid for obtaining maximal activity.
引用
收藏
页码:721 / 735
页数:15
相关论文
共 50 条
  • [1] Non-viral Gene Delivery and Therapeutics Targeting to Brain
    Liu, Yang
    Huang, Rongqin
    Jiang, Chen
    CURRENT NANOSCIENCE, 2011, 7 (01) : 55 - 70
  • [2] Non-viral gene delivery
    Behr, JP
    EUROCANCER 98, 1998, : 255 - 256
  • [3] Lipid-Based DNA Therapeutics: Hallmarks of Non-Viral Gene Delivery
    Buck, Jonas
    Grossen, Philip
    Cullis, Pieter R.
    Huwyler, Jorg
    Witzigmann, Dominik
    ACS NANO, 2019, 13 (04) : 3754 - 3782
  • [4] Intestinal delivery of non-viral gene therapeutics: physiological barriers and preclinical models
    O'Neill, Martin J.
    Bourre, Ludovic
    Melgar, Silvia
    O'Driscoll, Caitriona M.
    DRUG DISCOVERY TODAY, 2011, 16 (5-6) : 203 - 218
  • [5] Non-viral is superior to viral gene delivery
    Li, Shyh-Dar
    Huang, Leaf
    JOURNAL OF CONTROLLED RELEASE, 2007, 123 (03) : 181 - 183
  • [6] Non-viral nanocarriers for intracellular delivery of microRNA therapeutics
    Bai, Zhiman
    Wei, Jing
    Yu, Changmin
    Han, Xisi
    Qin, Xiaofei
    Zhang, Chengwu
    Liao, Wenzhen
    Li, Lin
    Huang, Wei
    JOURNAL OF MATERIALS CHEMISTRY B, 2019, 7 (08) : 1209 - 1225
  • [7] Cyclodextrins in non-viral gene delivery
    Lai, Wing-Fu
    BIOMATERIALS, 2014, 35 (01) : 401 - 411
  • [8] Non-viral gene delivery systems
    Legendre, JY
    Haensler, J
    Remy, JS
    M S-MEDECINE SCIENCES, 1996, 12 (12): : 1334 - 1341
  • [9] Materials for non-viral gene delivery
    Segura, T
    Shea, LD
    ANNUAL REVIEW OF MATERIALS RESEARCH, 2001, 31 : 25 - 46
  • [10] Non-Viral Gene Delivery Systems
    Faneca, Henrique
    PHARMACEUTICS, 2021, 13 (04)